MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results
45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, Md.,...
MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022
GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on...
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md., May 13, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on...
MaxCyte Reports First Quarter Financial Results
MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and Reiterates Milestone Revenue Guidance of $4 million...